Occurrence of intraocular air bubbles during intravitreal injections for retinopathy of prematurity

Sukgen E. A., Gunay M., KOÇLUK Y.

INTERNATIONAL OPHTHALMOLOGY, vol.37, no.1, pp.215-219, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 1
  • Publication Date: 2017
  • Doi Number: 10.1007/s10792-016-0257-9
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.215-219
  • Keywords: Bevacizumab, Ranibizumab, Intravitreal air bubbles, Intravitreal treatment, Retinopathy of prematurity, BEVACIZUMAB, PRETHRESHOLD
  • Karadeniz Technical University Affiliated: No


This study aims to present five cases with retinopathy of prematurity (ROP) who were found to have intraocular air bubbles after intravitreal injection (IVI) treatment. The medical records of 148 infants who underwent IVI for ROP were retrospectively reviewed and the ones who demonstrated post-injection intraocular air bubble formation were recruited. Of the 148 patients (31 babies received ranibizumab, 20 babies received aflibercept, 97 babies received bevacizumab), five were found to have intraocular air bubbles right after the IVI. Two infants received intravitreal ranibizumab and three received intravitreal bevacizumab injections. Although intraocular pressure increased temporarily, no intraocular sterile or infective reactions were observed in the postoperative period. The air bubble was found to resorb spontaneously within 72 h. The occurrence rate of the intravitreal air bubbles in our series was 3.37 % despite previously not been reported in the literature. Due to the intravitreal air injection risk, it is important to be more careful while preparing the intravitreal medication before treatment in premature babies.